Sequenom Announces Exclusive Licensing Agreement With Xenomics for Noninvasive Prenatal Diagnostics Using Transrenal DNA
Sequenom, Inc. (NASDAQ: SQNM), a leading provider of molecular diagnostic applications and genetic analysis products and services, today announced that it has licensed from Xenomics, Inc. (XNOM.PK), a developer of noninvasive molecular diagnostic tests, exclusive rights to patents (U.S. Patents 6,251,638 and RE 39,920, European Patent EP 0920539) for prenatal research and diagnostic products developed using fetal nucleic acids found in maternal urine. Financial terms were not disclosed.
“Sequenom’s significant position in noninvasive prenatal diagnostics is further enhanced by these patent rights,” stated Harry Stylli, Ph.D., President and Chief Executive Officer of Sequenom. “Use of transrenal fetal DNA in maternal urine is an innovative approach to prenatal diagnostics that we believe has compelling future commercial potential. We are continuing to evaluate strategic opportunities to broaden and deepen our IP position as we expand our SEQureDx(TM) franchise into new areas of prenatal diagnostics and build a long-term leadership position for Sequenom in this growth market.”
The license provides Sequenom with exclusive global rights to use transrenal fetal nucleic acids in maternal urine for noninvasive prenatal diagnostics and analysis on a technology-independent basis for all uses, excluding fetal gender determination solely by the presence of Y chromosome. The exclusive rights extend the SEQureDx prenatal diagnostic technology franchise that the Company is building by enabling the development of products for, and the protection of, an additional source of novel, noninvasive fetal sample and testing.
Sequenom’s Proprietary Noninvasive Prenatal Diagnostics
Sequenom’s commercial opportunities in prenatal diagnostics are built upon its SEQureDx technology and are enabled by the pioneering inventions and associated intellectual property rights that it has exclusively licensed from Isis Innovation Ltd., the technology transfer company of the University of Oxford, as well as The Chinese University of Hong Kong. Sequenom’s portfolio of noninvasive prenatal diagnostic patent rights and patent applications is platform-independent, includes genetic-analysis methods using circulating cell-free fetal nucleic acids from maternal samples, and also includes a portfolio of methylation and nucleic-acid markers. Sequenom is actively expanding its intellectual property position with new technology and new territories. Because Sequenom’s license rights are platform-independent, the rights provide exclusivity (with the narrow exception in Europe for RT-PCR-based Rhesus D tests) for development and commercialization of noninvasive prenatal tests on any platform and are not limited to the Company’s MassARRAY(R) platform.
Recent additions to Sequenom’s extensive IP portfolio include the exclusive rights to fundamental patent rights for digital PCR technologies and methods through a licensing agreement with Genomic Nanosystems, LLC, a wholly owned subsidiary of the Cytonix Corporation.
About Xenomics, Inc.
Xenomics is a molecular diagnostics company developing tests based on transrenal nucleic acids (Tr-DNA and Tr-RNA) and safe, simple urine collection techniques. The Company believes its proprietary technology has a broad range of detection / monitoring / screening applications, including for prenatal conditions, infectious diseases, tissue transplantation, neurodegenerative disorders, various tumors, and can open significant new markets in the molecular diagnostics field. Currently, Xenomics is focusing on implementation of its urinary DNA-based test for high-risk Human Papilloma Virus (HPV). Xenomics has a strong and broad IP portfolio of issued and pending patents covering different applications of the technology for molecular diagnostics. More information is available on the Company’s Web site, www.xenomics.com.
Sequenom is committed to providing the best genetic analysis products that translate the results of genomic science into solutions for noninvasive prenatal diagnostics, biomedical research, translational research and molecular medicine applications, and for research conducted in the agro (agricultural and livestock) industry. The Company’s proprietary MassARRAY system is a high-performance (in speed, accuracy and cost efficiency) nucleic acid analysis platform that quantitatively and precisely measures genetic target material and variations. The Company has exclusively licensed intellectual property rights for the development and commercialization of non-invasive prenatal genetic tests for use with the MassARRAY system and other platforms. For more information on Sequenom, please visit the Company’s Web site at www.sequenom.com.
Sequenom(R), MassARRAY(R) and SEQureDx(TM) are trademarks of Sequenom, Inc.
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the Company’s strategic and commercial opportunities and the compelling future commercial potential for use of transrenal fetal DNA in maternal urine for prenatal diagnostics, are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with the Company’s operating performance, demand for and market acceptance of the Company’s products, services, and technologies, new technology and product development and commercialization particularly for new technologies such as molecular diagnostics, and particularly noninvasive prenatal diagnostics involving use of transrenal fetal DNA in maternal urine, reliance upon the collaborative efforts of other parties, research and development progress, competition, intellectual property protection, government regulation, obtaining or maintaining regulatory approvals, and other risks detailed from time to time in the Company’s SEC (U.S. Securities and Exchange Commission) filings, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2007 and other documents subsequently filed with or furnished to the SEC. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.